DK3186259T3 - TETRAHYDRONAPHTHALENE DERIVATIVES INHIBITING MCL-1 PROTEIN - Google Patents

TETRAHYDRONAPHTHALENE DERIVATIVES INHIBITING MCL-1 PROTEIN Download PDF

Info

Publication number
DK3186259T3
DK3186259T3 DK15772048.3T DK15772048T DK3186259T3 DK 3186259 T3 DK3186259 T3 DK 3186259T3 DK 15772048 T DK15772048 T DK 15772048T DK 3186259 T3 DK3186259 T3 DK 3186259T3
Authority
DK
Denmark
Prior art keywords
compound
mmol
chloro
naphthalene
spiro
Prior art date
Application number
DK15772048.3T
Other languages
Danish (da)
English (en)
Inventor
Yunxiao Li
Mike Elias Lizarzaburu
Brian S Lucas
Nick A Paras
Joshua Taygerly
Marc Vimolratana
Xianghong Wang
Ming Yu
Manuel Zancanella
Liusheng Zhu
Buenrostro Ana Gonzalez
Zhihong Li
Sean P Brown
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK3186259T3 publication Critical patent/DK3186259T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK15772048.3T 2014-08-29 2015-08-28 TETRAHYDRONAPHTHALENE DERIVATIVES INHIBITING MCL-1 PROTEIN DK3186259T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043929P 2014-08-29 2014-08-29
PCT/US2015/047472 WO2016033486A1 (en) 2014-08-29 2015-08-28 Tetrahydronaphthalene derivatives that inhibit mcl-1 protein

Publications (1)

Publication Number Publication Date
DK3186259T3 true DK3186259T3 (en) 2019-02-25

Family

ID=54238507

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15772048.3T DK3186259T3 (en) 2014-08-29 2015-08-28 TETRAHYDRONAPHTHALENE DERIVATIVES INHIBITING MCL-1 PROTEIN

Country Status (41)

Country Link
US (7) US9562061B2 (en:Method)
EP (2) EP3424931B1 (en:Method)
JP (1) JP6502479B2 (en:Method)
KR (1) KR102466351B1 (en:Method)
CN (1) CN107001387B (en:Method)
AP (1) AP2017009827A0 (en:Method)
AR (1) AR101729A1 (en:Method)
AU (1) AU2015308735B2 (en:Method)
BR (1) BR112017004209B1 (en:Method)
CA (1) CA2959615C (en:Method)
CL (1) CL2017000469A1 (en:Method)
CO (1) CO2017002998A2 (en:Method)
CR (1) CR20170116A (en:Method)
CY (1) CY1121195T1 (en:Method)
DK (1) DK3186259T3 (en:Method)
EA (1) EA031223B1 (en:Method)
ES (2) ES2706309T3 (en:Method)
HR (1) HRP20190053T1 (en:Method)
HU (1) HUE041806T2 (en:Method)
IL (2) IL250843B (en:Method)
JO (1) JO3474B1 (en:Method)
LT (1) LT3186259T (en:Method)
MA (1) MA40111B1 (en:Method)
ME (1) ME03313B (en:Method)
MX (1) MX379155B (en:Method)
MY (1) MY176235A (en:Method)
PE (1) PE20170892A1 (en:Method)
PH (1) PH12017500367B1 (en:Method)
PL (1) PL3186259T3 (en:Method)
PT (1) PT3186259T (en:Method)
RS (1) RS58276B1 (en:Method)
SG (1) SG11201701525WA (en:Method)
SI (1) SI3186259T1 (en:Method)
SM (1) SMT201900048T1 (en:Method)
TN (1) TN2017000067A1 (en:Method)
TR (1) TR201901312T4 (en:Method)
TW (1) TWI676628B (en:Method)
UA (1) UA118233C2 (en:Method)
UY (1) UY36285A (en:Method)
WO (1) WO2016033486A1 (en:Method)
ZA (2) ZA201701763B (en:Method)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) * 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3988555A1 (en) * 2017-08-15 2022-04-27 AbbVie Inc. Macrocyclic mcl-1 inhibitors and methods of use
UY37844A (es) * 2017-08-15 2019-03-29 Abbvie Inc Inhibidores de mcl-1 macrocíclicos y métodos de uso
US11364248B2 (en) 2017-08-18 2022-06-21 Amgen Inc. Compounds that inhibit Mcl-1 protein
US11279712B2 (en) 2017-08-29 2022-03-22 Amgen Inc. Macrocyclic compounds that inhibit MCL-1 protein
EP3762393B1 (en) 2018-03-05 2023-01-11 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
US10703733B2 (en) 2018-05-14 2020-07-07 Gilead Sciences, Inc. MCL-1 inhibitors
WO2020097577A1 (en) * 2018-11-09 2020-05-14 Prelude Therapeutics, Incorporated Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
CN112867722B (zh) * 2019-01-18 2022-09-23 苏州亚盛药业有限公司 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers)
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體-藥物結合物及使用方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP7617861B2 (ja) * 2019-06-21 2025-01-20 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1の大環状阻害剤
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ, インコーポレイテッド Flt3l-fc融合タンパク質及び使用方法
JP7573591B2 (ja) 2019-07-09 2024-10-25 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1阻害剤としての大環状スピロ環誘導体
EP3771469A1 (en) * 2019-07-30 2021-02-03 Amgen, Inc Formulations and dosages for administering a compound that inhibits mcl1 protein
CN112479876B (zh) * 2019-09-12 2023-07-21 苏州亚盛药业有限公司 氧氮杂环庚烷类螺环化合物、中间体及其制备方法
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MY209360A (en) 2019-10-31 2025-07-03 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ras阻害剤
MX2022005357A (es) * 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020391106B2 (en) * 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
KR20220142484A (ko) 2020-02-14 2022-10-21 조운스 테라퓨틱스, 인크. Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
MX2022010299A (es) * 2020-02-21 2022-11-14 Janssen Pharmaceutica Nv Derivados macrocíclicos de indol como inhibidores de mcl-1.
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Mcl−1化合物のメチル化
US20230212191A1 (en) * 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ, インコーポレイテッド Cd73阻害性2,4-ジオキソピリミジン化合物
CA3181189A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of vinylic alcohol intermediates
WO2021225833A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of sulfonamide intermediates
TWI867217B (zh) * 2020-05-06 2024-12-21 美商安進公司 乙烯基環丁基中間體之合成
MX2022013871A (es) 2020-05-06 2022-11-30 Amgen Inc Sintesis de productos intermedios de alcohol protegido vinilico.
TWI827924B (zh) * 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
WO2021250102A1 (en) 2020-06-10 2021-12-16 Janssen Pharmaceutica Nv Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
US20230365588A1 (en) * 2020-09-03 2023-11-16 Amgen Inc. Diol desymmetrization by nucleophilic aromatic substitution
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ras抑制劑
JP7659630B2 (ja) * 2020-11-19 2025-04-09 ギリアード サイエンシーズ, インコーポレイテッド 大環状mcl1阻害剤を調製するための方法及び中間体
KR20230138444A (ko) 2020-11-24 2023-10-05 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
AU2021385537A1 (en) * 2020-11-25 2023-06-22 Amgen Inc. Enantioselective alkenylation of aldehydes
US20240041884A1 (en) 2020-12-07 2024-02-08 Cellestia Biotech Ag Pharmaceutical Combinations for Treating Cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
CN116670141A (zh) 2020-12-17 2023-08-29 詹森药业有限公司 作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
BR112023020877A2 (pt) 2021-04-26 2023-12-12 Janssen Pharmaceutica Nv 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1
US12252497B2 (en) 2021-05-05 2025-03-18 Revolution Medicines, Inc. Ras inhibitors
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
CN118251398A (zh) 2021-11-16 2024-06-25 詹森药业有限公司 作为mcl-1抑制剂的大环2-氨基-丁-3-烯酰胺
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
MX2024011279A (es) 2022-03-17 2024-09-25 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos.
CA3254506A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH -2
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023249146A1 (en) 2022-04-05 2024-10-10 Amgen Inc. Salt forms and solvates of mci-1 antagonists
US20240140966A1 (en) 2022-04-05 2024-05-02 Amgen Inc. Amorphous and crystalline forms of mcl-1 antagonists
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
EP1904047B1 (en) * 2005-07-07 2013-01-02 Abbott Laboratories Apoptosis promoters
MX2009011211A (es) * 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
AU2008281849B2 (en) * 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2470527A4 (en) * 2009-08-20 2013-02-27 Merck Sharp & Dohme ETHER-benzotriazole
KR20120060234A (ko) * 2009-10-08 2012-06-11 샌포드-번햄 메디칼 리서치 인스티튜트 항암제로서의 아포고시폴론 유도체
US20130035304A1 (en) * 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
US9486422B2 (en) 2011-10-06 2016-11-08 The Regents Of The University Of Michigan Small molecule inhibitors of Mcl-1 and the uses of thereof
WO2013149124A1 (en) * 2012-03-29 2013-10-03 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein

Also Published As

Publication number Publication date
EP3424931B1 (en) 2020-02-12
JP2017525730A (ja) 2017-09-07
MX379155B (es) 2025-03-11
CR20170116A (es) 2017-04-28
US10836779B2 (en) 2020-11-17
AR101729A1 (es) 2017-01-11
ZA201802865B (en) 2022-05-25
ME03313B (me) 2019-10-20
TW201625645A (zh) 2016-07-16
MX2017002656A (es) 2017-10-12
US11001598B2 (en) 2021-05-11
PE20170892A1 (es) 2017-07-12
AP2017009827A0 (en) 2017-03-31
CA2959615C (en) 2023-01-17
US20160068545A1 (en) 2016-03-10
US20230271981A1 (en) 2023-08-31
JO3474B1 (ar) 2020-07-05
US20190023720A1 (en) 2019-01-24
EP3186259A1 (en) 2017-07-05
PL3186259T3 (pl) 2019-04-30
US10494381B2 (en) 2019-12-03
TN2017000067A1 (en) 2018-07-04
CO2017002998A2 (es) 2017-07-19
HUE041806T2 (hu) 2019-05-28
LT3186259T (lt) 2019-02-25
TWI676628B (zh) 2019-11-11
PH12017500367A1 (en) 2017-07-10
IL250843B (en) 2018-03-29
EP3186259B1 (en) 2018-12-19
US20170088560A1 (en) 2017-03-30
HRP20190053T1 (hr) 2019-02-22
PT3186259T (pt) 2019-02-06
MA40111B1 (fr) 2018-12-31
MY176235A (en) 2020-07-24
US10100063B2 (en) 2018-10-16
TR201901312T4 (tr) 2019-02-21
MA40111A1 (fr) 2018-06-29
NZ729768A (en) 2021-06-25
CY1121195T1 (el) 2020-05-29
SG11201701525WA (en) 2017-03-30
US20210040120A1 (en) 2021-02-11
RS58276B1 (sr) 2019-03-29
AU2015308735A1 (en) 2017-03-23
UY36285A (es) 2016-04-01
WO2016033486A1 (en) 2016-03-03
ES2706309T3 (es) 2019-03-28
ES2777478T3 (es) 2020-08-05
CL2017000469A1 (es) 2017-11-03
SI3186259T1 (sl) 2019-03-29
EA031223B1 (ru) 2018-12-28
CA2959615A1 (en) 2016-03-03
EP3424931A3 (en) 2019-02-20
US9562061B2 (en) 2017-02-07
IL257942B (en) 2020-05-31
CN107001387A (zh) 2017-08-01
UA118233C2 (uk) 2018-12-10
PH12017500367B1 (en) 2017-07-10
US20190016736A1 (en) 2019-01-17
KR20170043661A (ko) 2017-04-21
US20200062780A1 (en) 2020-02-27
IL250843A0 (en) 2017-04-30
JP6502479B2 (ja) 2019-04-17
EP3424931A2 (en) 2019-01-09
EA201790492A1 (ru) 2017-07-31
AU2015308735B2 (en) 2019-03-14
KR102466351B1 (ko) 2022-11-10
US12024529B2 (en) 2024-07-02
SMT201900048T1 (it) 2019-02-28
IL257942A (en) 2018-05-31
BR112017004209B1 (pt) 2022-08-09
US11685747B2 (en) 2023-06-27
CN107001387B (zh) 2019-03-05
BR112017004209A2 (pt) 2018-07-31
ZA201701763B (en) 2018-08-29

Similar Documents

Publication Publication Date Title
US12024529B2 (en) Compounds that inhibit MCL-1 protein
EP3601297B9 (en) Compounds that inhibit mcl-1 protein
EP3668878A1 (en) Compounds that inhibit mcl-1 protein
EP3762393A1 (en) Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
NZ729768B2 (en) Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
HK40020443B (en) Compounds that inhibit mcl-1 protein
HK40020443A (en) Compounds that inhibit mcl-1 protein